Crizanlizumab
Orphan Drug Cold Chain RequiredFDA Approved
Description
Crizanlizumab is a humanized IgG2 monoclonal antibody that binds to P-selectin, blocking interactions with P-selectin glycoprotein ligand-1 (PSGL-1). This reduces vaso-occlusion in patients with sickle cell disease, a mechanism that may also be relevant in other vascular disorders.
Indications & Therapeutic Use
Prevention of vaso-occlusive crises in sickle cell disease
Linked Diseases:
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Crizanlizumab
| Generic Name | Crizanlizumab |
| Brands | 1 brand available |
| Active Ingredient | Crizanlizumab |
| Drug Class | Prevention of vaso-occlusive crises in sickle cell disease |
| Manufacturer | Novartis |
| Dosage Forms | IV infusion, 5mg/mL |
| Medical Code | B06AC07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01895361 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes